WO2011104414A3 - Compuestos para el tratamiento de alzheimer - Google Patents

Compuestos para el tratamiento de alzheimer Download PDF

Info

Publication number
WO2011104414A3
WO2011104414A3 PCT/ES2011/070122 ES2011070122W WO2011104414A3 WO 2011104414 A3 WO2011104414 A3 WO 2011104414A3 ES 2011070122 W ES2011070122 W ES 2011070122W WO 2011104414 A3 WO2011104414 A3 WO 2011104414A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
compounds
amyloid deposits
treating alzheimer
formation
Prior art date
Application number
PCT/ES2011/070122
Other languages
English (en)
French (fr)
Other versions
WO2011104414A2 (es
Inventor
Carlos Matute Almau
José Luis ZUGAZA GURRUCHAGA
Original Assignee
Universidad Del País Vasco
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Del País Vasco filed Critical Universidad Del País Vasco
Publication of WO2011104414A2 publication Critical patent/WO2011104414A2/es
Publication of WO2011104414A3 publication Critical patent/WO2011104414A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Los compuestos inhibidores de Rac1 pueden ser utilizados para el tratamiento de enfermedades asociadas a la formación de depósitos amiloideos, entre las que se encuentra la enfermedad de Alzheimer. Los niveles de activación de Rac1 en una célula tratada con una proteína amiloidea pueden ser utilizados para identificar compuestos capaces de inhibir la muerte celular inducida por depósitos amiloideos potencialmente útiles en el tratamiento de enfermedades asociadas a la formación de depósitos amiloideos.
PCT/ES2011/070122 2010-02-25 2011-02-25 Compuestos para el tratamiento de alzheimer WO2011104414A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP201030269 2010-02-25
ES201030269A ES2377086B1 (es) 2010-02-25 2010-02-25 Compuestos para el tratamiento de alzheimer.

Publications (2)

Publication Number Publication Date
WO2011104414A2 WO2011104414A2 (es) 2011-09-01
WO2011104414A3 true WO2011104414A3 (es) 2011-11-03

Family

ID=44507297

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2011/070122 WO2011104414A2 (es) 2010-02-25 2011-02-25 Compuestos para el tratamiento de alzheimer

Country Status (2)

Country Link
ES (1) ES2377086B1 (es)
WO (1) WO2011104414A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210093970A (ko) * 2018-11-21 2021-07-28 아이오니스 파마수티컬즈, 인코포레이티드 프리온 발현을 감소시키기 위한 화합물 및 방법
CN109925510A (zh) * 2019-04-11 2019-06-25 北京卓凯生物技术有限公司 Rac1活性抑制剂在制备治疗阿尔茨海默病的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090093471A1 (en) * 2005-07-27 2009-04-09 Laurent Desire Methods of Treating Nervous Disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090093471A1 (en) * 2005-07-27 2009-04-09 Laurent Desire Methods of Treating Nervous Disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DESIRE L. ET AL.: "RAC1 inhibition targets amyloid precursor protein processing by gamma-secretase and decreases Abeta production in vitro and in vivo", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, 8 September 2005 (2005-09-08), pages 37516 - 37525 *
TIEDE I. ET AL: "CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 111, no. 8, April 2003 (2003-04-01), pages 1133 - 1145 *
WANG P.-L. ET AL: "Rac1 inhibition negatively regulates transcriptional activity of the amyloid precursor protein gene", JOURNAL OF NEUROSCIENCE RESEARCH, vol. 87, 6 March 2009 (2009-03-06), pages 2105 - 2114 *
WANSA K.D. ET AL: "TRAP220 is modulated by the antineoplastic agent 6-Mercaptopurine, and mediates the activation of the NR4A subgroup of nuclear receptors", J. MOL. ENDOCRINOL., vol. 34, no. 3, June 2005 (2005-06-01), pages 835 - 848 *

Also Published As

Publication number Publication date
ES2377086A1 (es) 2012-03-22
WO2011104414A2 (es) 2011-09-01
ES2377086B1 (es) 2013-07-01

Similar Documents

Publication Publication Date Title
WO2012062925A3 (en) Compounds and methods for treating pain
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
WO2014031928A3 (en) Heterocyclic modulators of hif activity for treatment of disease
WO2012149478A3 (en) Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
EA201690745A1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"
EA201691354A1 (ru) Терапевтические ингибирующие соединения
MX351943B (es) Compuestos inhibidores de metaloenzima.
EA201491221A1 (ru) Новые молекулы, ингибирующие jnk, для лечения различных болезней
EA201491151A1 (ru) Соединения, ингибирующие металлоферменты
BR112015020466A2 (pt) inibidores de cdc7
MX2016001186A (es) Diagnostico y terapia de cancer que implica celulas madre cancerosas.
IN2014DN00286A (es)
EA201201374A1 (ru) Лечение атаксии-телеангиэктазии
TR201820051T4 (tr) Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması
IN2014MN00093A (es)
WO2011133875A3 (en) Metalloenzyme inhibitor compounds
EA201391485A1 (ru) Способы и композиции для лечения нейродегенеративных заболеваний
WO2014031933A3 (en) Heterocyclic modulators of hif activity for treatment of disease
WO2014031936A3 (en) Heterocyclic modulators of hif activity for treatment of disease
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
WO2011091366A3 (en) Methods of treating or preventing periodontitis and diseases associated with periodontitis
MX348941B (es) Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo.
EA201390704A1 (ru) Соединения, ингибирующие металлоферменты
WO2013098416A3 (fr) Composes anti-douleur

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11746905

Country of ref document: EP

Kind code of ref document: A2